Connectus Wealth LLC Invests $828,000 in Sanofi (NASDAQ:SNY)

Connectus Wealth LLC bought a new position in Sanofi (NASDAQ:SNYFree Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 16,649 shares of the company’s stock, valued at approximately $828,000.

Several other hedge funds and other institutional investors have also recently made changes to their positions in SNY. Rise Advisors LLC lifted its stake in shares of Sanofi by 98.4% in the fourth quarter. Rise Advisors LLC now owns 506 shares of the company’s stock worth $25,000 after buying an additional 251 shares in the last quarter. Salem Investment Counselors Inc. purchased a new position in shares of Sanofi during the fourth quarter valued at approximately $27,000. Venturi Wealth Management LLC raised its holdings in shares of Sanofi by 163.5% during the fourth quarter. Venturi Wealth Management LLC now owns 535 shares of the company’s stock valued at $27,000 after purchasing an additional 332 shares during the last quarter. Frazier Financial Advisors LLC purchased a new position in shares of Sanofi during the fourth quarter valued at approximately $28,000. Finally, McIlrath & Eck LLC raised its holdings in shares of Sanofi by 143.3% during the fourth quarter. McIlrath & Eck LLC now owns 613 shares of the company’s stock valued at $30,000 after purchasing an additional 361 shares during the last quarter. Institutional investors own 10.04% of the company’s stock.

Sanofi Stock Performance

Shares of NASDAQ SNY opened at $48.86 on Tuesday. The firm has a fifty day moving average price of $48.32 and a 200-day moving average price of $48.46. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.27 and a quick ratio of 0.87. The stock has a market cap of $123.61 billion, a PE ratio of 24.55, a price-to-earnings-growth ratio of 1.53 and a beta of 0.60. Sanofi has a 1 year low of $42.63 and a 1 year high of $55.72.

Sanofi (NASDAQ:SNYGet Free Report) last issued its earnings results on Thursday, April 25th. The company reported $0.96 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.96. Sanofi had a net margin of 10.52% and a return on equity of 26.25%. The firm had revenue of $11.36 billion during the quarter, compared to analyst estimates of $11.75 billion. Equities analysts anticipate that Sanofi will post 4.11 earnings per share for the current fiscal year.

Sanofi Increases Dividend

The business also recently announced an annual dividend, which was paid on Thursday, June 6th. Investors of record on Friday, May 10th were given a dividend of $1.478 per share. This is a positive change from Sanofi’s previous annual dividend of $1.38. The ex-dividend date was Thursday, May 9th. This represents a dividend yield of 2.98%. Sanofi’s dividend payout ratio is currently 74.37%.

Wall Street Analyst Weigh In

Separately, StockNews.com cut shares of Sanofi from a “strong-buy” rating to a “buy” rating in a report on Tuesday, February 27th. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat, Sanofi has an average rating of “Moderate Buy” and an average target price of $55.00.

Read Our Latest Research Report on SNY

Sanofi Profile

(Free Report)

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.

See Also

Institutional Ownership by Quarter for Sanofi (NASDAQ:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.